Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.

Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.

Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.

Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.

Abstract: The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric antigen receptor genetically modified T cell immunotherapy and methods for manufacturing such immunotherapy. Some aspects of the disclosure relate to methods of determining objective response of a patient to a T cell immunotherapy based on the levels of attributes prior to and after administration of the immunotherapy to the patient.

Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.

Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.

Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.

Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.

Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.

Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.

Abstract: A method and apparatus for managing complex presentation objects using globally-unique identifiers. Downloaded objects are identified by globally-unique identifiers to maintain object integrity and to facilitate capturing downloaded objects for reuse without additional download time overhead. An object may be referenced by selected indicia, such as a name, a globally-unique identifier or a globally-unique identifier and an object locator, The object is located by the selected indicia. Then, a decision is made whether to allow capture of the object based upon whether the selected indicia includes a globally-unique identifier and is secure.

Abstract: A method and apparatus for managing complex presentation objects using globally-unique identifiers. Downloaded objects are identified by globally-unique identifiers to maintain object integrity and to facilitate capturing downloaded objects for reuse without additional download time overhead. An object may be referenced by selected indicia, such as a name, a globally-unique identifier or a globally-unique identifier and an object locator, The object is located by the selected indicia. Then, a decision is made whether to allow capture of the object based upon whether the selected indicia includes a globally-unique identifier and is secure.

Abstract: A method and apparatus for managing complex presentation objects using globally-unique identifiers. Downloaded objects are identified by globally-unique identifiers to maintain object integrity and to facilitate capturing downloaded objects for reuse without additional download time overhead. An object may be referenced by selected indicia, such as a name, a globally-unique identifier or a globally-unique identifier and an object locator, The object is located by the selected indicia. Then, a decision is made whether to allow capture of the object based upon whether the selected indicia includes a globally-unique identifier and is secure.